FIS Named to FORTUNE's 2022 Most Admired Company List

Key facts:

  • FIS received high marks for global competitiveness, financial soundness, innovation, quality of products and services, people management, social responsibility, and use of corporate assets.
  • FIS was only one of a select number of financial technology providers on the 2022 FORTUNE list.

Financial technology leader FIS ® (NYSE: FIS) announced today that it has been named to the FORTUNE Magazine 2022 World's Most Admired Company list.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220202005648/en/

FIS has been named a World's Most Admired Company by FORTUNE magazine.

FIS has been named a World's Most Admired Company by FORTUNE magazine.

The FORTUNE study measures companies with the strongest reputation within their industries. FIS was one of only a small number of financial technology providers on the 2022 FORTUNE list. FIS received high marks for global competitiveness, financial soundness, innovation, quality of products and services, people management, social responsibility, and use of corporate assets.

"It's an honor to be recognized once again by our peers for FORTUNE's Most Admired Companies list," said Gary Norcross, FIS chairman and CEO. "We're proud of this recognition because it underscores our differentiating ability to unlock a broad spectrum of financial technology to advance how the world pays, banks and invests."

The FORTUNE World's Most Admired Companies list is based on survey results from thousands of executives, directors and analysts at companies worldwide. Respondents rate companies in their own industry on nine factors, which include investment value as well as social responsibility. Each respondent then selects 10 companies he or she admires most.

About FIS

FIS is a leading provider of technology solutions for merchants, banks and capital markets firms globally. Our employees are dedicated to advancing the way the world pays, banks and invests by applying our scale, deep expertise and data-driven insights. We help our clients use technology in innovative ways to solve business-critical challenges and deliver superior experiences for their customers. Headquartered in Jacksonville, Florida, FIS ranks #241 on the 2021 Fortune 500 and is a member of Standard & Poor's 500® Index. To learn more, visit www.fisglobal.com . Follow FIS on Facebook , LinkedIn and Twitter ( @FISGlobal ).

Kim Snider, 904.438.6278
Senior Vice President
FIS Global Marketing and Communications
kim.snider@fisglobal.com

News Provided by Business Wire via QuoteMedia

FIS
The Conversation (0)
Brunswick Continues to Intersect Lithium Mineralization on Globex's Lac Escale Royalty Property

Brunswick Continues to Intersect Lithium Mineralization on Globex's Lac Escale Royalty Property

GLOBEX MINING ENTERPRISES INC. (GMX Toronto Stock Exchange, G1MN Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exch anges and GLBXF OTCQX International in the US) is pleased to report that Brunswick Exploration Inc. (BRW-TSXV, BRWXF-OTCQB) in a press release today, announced additional wide intersections of lithium mineralization on Globex's Lac Escale royalty claims, a part of Brunswick's Mirage property.

Intersections include 36 meters grading 1.51% Li 2 O in Hole MR-24-102 and 1.32% Li 2 O over 28 metres in Hole MR-24-101. A total of 24 drill holes were completed in the winter drill program. Please access Brunswick's press release of today's date for further details.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies (TSXV:ZCT)

Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company is preparing to conduct a full preclinical study of its final human-use device in up to 24 additional sheep.

The company has successfully completed a two sheep protocol pilot trial in November 2023, and is now preparing to expand the study. The ZC-1-A device was confirmed as 100% safe for use, with findings concluded from the Shamir Medical Center.

Keep reading...Show less

Latest Press Releases

Related News

×